TRAW Form 3 shows director status and no beneficial ownership

Rhea-AI Filing Summary

Traws Pharma (TRAW) filed a Form 3 for director John Leaman, reporting initial beneficial ownership status as of 10/01/2025.

The filing states that no securities are beneficially owned. This is a routine Section 16 compliance disclosure establishing the insider’s baseline holdings at the time he became a reporting person.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Leaman John Harold

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTON PA 18940

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2025

3. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ John Leaman	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TRAW disclose in this Form 3?

It reports director John Leaman’s initial beneficial ownership status as of 10/01/2025, stating no securities are beneficially owned.

Who is the reporting person in TRAW’s Form 3?

The Form 3 is filed by John Leaman, identified as a Director.

What is the event date for TRAW’s Form 3?

The event date requiring the statement is 10/01/2025.

Does the TRAW Form 3 show any stock or derivative holdings?

No. The filing states No securities are beneficially owned.

Is this Form 3 a joint filing?

No. It indicates Form filed by One Reporting Person.

What is the nature of the insider’s relationship to TRAW?

The filer is a Director of Traws Pharma, Inc.